HRP20100693T1 - Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora - Google Patents
Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora Download PDFInfo
- Publication number
- HRP20100693T1 HRP20100693T1 HR20100693T HRP20100693T HRP20100693T1 HR P20100693 T1 HRP20100693 T1 HR P20100693T1 HR 20100693 T HR20100693 T HR 20100693T HR P20100693 T HRP20100693 T HR P20100693T HR P20100693 T1 HRP20100693 T1 HR P20100693T1
- Authority
- HR
- Croatia
- Prior art keywords
- azonia
- bicyclo
- hydroxy
- octane bromide
- acetoxy
- Prior art date
Links
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 title 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 title 1
- 150000008584 quinuclidines Chemical class 0.000 title 1
- -1 9H-fluoren-9-yl Chemical group 0.000 claims abstract 27
- 150000001875 compounds Chemical class 0.000 claims abstract 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 22
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims abstract 16
- 239000001257 hydrogen Substances 0.000 claims abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 10
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 claims abstract 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000005842 heteroatom Chemical group 0.000 claims abstract 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 8
- 239000001301 oxygen Chemical group 0.000 claims abstract 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 8
- 229910052717 sulfur Chemical group 0.000 claims abstract 8
- 239000011593 sulfur Chemical group 0.000 claims abstract 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 7
- 125000005843 halogen group Chemical group 0.000 claims abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 2
- PTHNRUQVXLGKKT-WTHDWRSPSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CC(=O)NC=1C=CON=1 PTHNRUQVXLGKKT-WTHDWRSPSA-N 0.000 claims abstract 2
- KVYFPKJRJWDXCT-LWOCSEGBSA-O [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CC(=O)NC1=CN=CC=N1 KVYFPKJRJWDXCT-LWOCSEGBSA-O 0.000 claims abstract 2
- ZPFCXHFVCOFWOZ-XTBFPHCZSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CC(=O)NC1=CC=NC=N1 ZPFCXHFVCOFWOZ-XTBFPHCZSA-N 0.000 claims abstract 2
- 239000012907 medicinal substance Substances 0.000 claims 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 3
- 229940124630 bronchodilator Drugs 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- PWSXXTLDLCIUGO-UTEXUTGQSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 PWSXXTLDLCIUGO-UTEXUTGQSA-N 0.000 claims 2
- NVQBJTIINOFPEC-OFIQDHIESA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=NC=NC=N1 NVQBJTIINOFPEC-OFIQDHIESA-N 0.000 claims 2
- DQWQUUWAYXIMGT-ZVPZRTFFSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 DQWQUUWAYXIMGT-ZVPZRTFFSA-N 0.000 claims 2
- CFMGCNDIOKQGHM-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 CFMGCNDIOKQGHM-AYFIPJBYSA-N 0.000 claims 2
- SLCAXYRZANJZTL-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CC=N1 SLCAXYRZANJZTL-SGFHCSRJSA-N 0.000 claims 2
- 239000000048 adrenergic agonist Substances 0.000 claims 2
- 230000000954 anitussive effect Effects 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 229940124584 antitussives Drugs 0.000 claims 2
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 206010027654 Allergic conditions Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 claims 1
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- MXTHDVYBJMKRAW-TWBGCDCQSA-N [(2r)-2-methyl-1-[(5-methyl-1,2-oxazol-3-yl)carbamoyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide Chemical compound [Br-].C1([C@H]([N+]2(CCC1CC2)C(=O)NC1=NOC(C)=C1)C)OC(=O)C(O)(C=1C=CC=CC=1)C1=CC=CC=C1 MXTHDVYBJMKRAW-TWBGCDCQSA-N 0.000 claims 1
- LBHUBPVFRVTKRE-NJSXXHIRSA-N [(3R)-1-[2-amino-1-(1,2-oxazol-3-yl)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate phosphate Chemical compound [O-]P([O-])([O-])=O.C1CC([C@H](C2)OC(=O)[C@@](O)(C3CCCC3)C=3C=CC=CC=3)CC[N+]12C(C(=O)N)C=1C=CON=1.C1CC([C@H](C2)OC(=O)[C@@](O)(C3CCCC3)C=3C=CC=CC=3)CC[N+]12C(C(=O)N)C=1C=CON=1.C1CC([C@H](C2)OC(=O)[C@@](O)(C3CCCC3)C=3C=CC=CC=3)CC[N+]12C(C(=O)N)C=1C=CON=1 LBHUBPVFRVTKRE-NJSXXHIRSA-N 0.000 claims 1
- NDKPGOIGMAPCKZ-ADFHNETRSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 NDKPGOIGMAPCKZ-ADFHNETRSA-N 0.000 claims 1
- CZDAJDIMEGEBST-UXJVTRAKSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21C(=O)NC1=CC=CN=N1 CZDAJDIMEGEBST-UXJVTRAKSA-N 0.000 claims 1
- PPDAIKJPFBAEPV-BDVUIUMHSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21C(=O)NC1=CC=CN=N1 PPDAIKJPFBAEPV-BDVUIUMHSA-N 0.000 claims 1
- WOZUKJBPTBJMRI-AYFIPJBYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 WOZUKJBPTBJMRI-AYFIPJBYSA-N 0.000 claims 1
- ASIIWQLNQRMJJF-BDVUIUMHSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 ASIIWQLNQRMJJF-BDVUIUMHSA-N 0.000 claims 1
- MDRKZBWOEKSIQL-ZVPZRTFFSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 MDRKZBWOEKSIQL-ZVPZRTFFSA-N 0.000 claims 1
- HKJJONBLZRQIOO-AYFIPJBYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 HKJJONBLZRQIOO-AYFIPJBYSA-N 0.000 claims 1
- HOYHGTSNECKWMY-BDVUIUMHSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 HOYHGTSNECKWMY-BDVUIUMHSA-N 0.000 claims 1
- SZIQGRZMRQJLJF-PKPSOOLGSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 SZIQGRZMRQJLJF-PKPSOOLGSA-N 0.000 claims 1
- KGSIOSOOXZMXFH-SFZOXUKMSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C1=COC=C1)(O)C1CCCC1 KGSIOSOOXZMXFH-SFZOXUKMSA-N 0.000 claims 1
- GAZDVSXUYQWHSZ-QVOXVMGDSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 GAZDVSXUYQWHSZ-QVOXVMGDSA-N 0.000 claims 1
- DZCKMHXNWKSWTB-PKPSOOLGSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)C(=O)NC=1N=NC=CC=1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 DZCKMHXNWKSWTB-PKPSOOLGSA-N 0.000 claims 1
- YVFLUJNRTOMJLQ-UXJVTRAKSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21C(=O)NC1=CC=CN=N1 YVFLUJNRTOMJLQ-UXJVTRAKSA-N 0.000 claims 1
- UESPJDKHOUCQCC-BDVUIUMHSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21C(=O)NC1=CC=CN=N1 UESPJDKHOUCQCC-BDVUIUMHSA-N 0.000 claims 1
- CHLFOCRTPQDCQG-SGFHCSRJSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 CHLFOCRTPQDCQG-SGFHCSRJSA-N 0.000 claims 1
- GKTUUSSQPLEKSD-SGFHCSRJSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 GKTUUSSQPLEKSD-SGFHCSRJSA-N 0.000 claims 1
- ZDNIVRNFHOJTJA-PMLWWUNYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 ZDNIVRNFHOJTJA-PMLWWUNYSA-N 0.000 claims 1
- IVYCCLOHYSTYRR-PMLWWUNYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 IVYCCLOHYSTYRR-PMLWWUNYSA-N 0.000 claims 1
- WASPVIDRFWKIFH-PMLWWUNYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3C4=CC=CC=C4C4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 WASPVIDRFWKIFH-PMLWWUNYSA-N 0.000 claims 1
- IINGMDFVUYFQHG-PMLWWUNYSA-N [(3r)-1-(pyridazin-3-ylcarbamoyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)[N+]21C(=O)NC1=CC=CN=N1 IINGMDFVUYFQHG-PMLWWUNYSA-N 0.000 claims 1
- XTOAYDTZDJBLAL-RSYCBKOKSA-N [(3r)-1-[1-(1,2-oxazol-3-ylamino)-1-oxopropan-2-yl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-diphenylacetate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C(O)(C=3C=CC=CC=3)C=3C=CC=CC=3)CC[N+]12C(C)C(=O)NC=1C=CON=1 XTOAYDTZDJBLAL-RSYCBKOKSA-N 0.000 claims 1
- JCPYBEFKFGQQBW-DMWRAEOSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)[N+]21CC(=O)NC=1C=CON=1 JCPYBEFKFGQQBW-DMWRAEOSSA-N 0.000 claims 1
- LYEUZKSCFWFFMP-OFIQDHIESA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(2-chlorophenyl)-2-hydroxyacetate;bromide Chemical group [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3C(=CC=CC=3)Cl)C=3C(=CC=CC=3)Cl)[N+]21CC(=O)NC=1C=CON=1 LYEUZKSCFWFFMP-OFIQDHIESA-N 0.000 claims 1
- JXEBVFQBPQIYOH-FKYYSRDKSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC=1C=CON=1 JXEBVFQBPQIYOH-FKYYSRDKSA-N 0.000 claims 1
- HZGHGUPFITZHEX-GXVQUIFISA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-diphenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC1=NOC=C1)C(=O)C(C=1C=CC=CC=1)C1=CC=CC=C1 HZGHGUPFITZHEX-GXVQUIFISA-N 0.000 claims 1
- QNGBQXNPFDMABV-WULMZJJMSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-diphenylpropanoate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(C)(C=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 QNGBQXNPFDMABV-WULMZJJMSA-N 0.000 claims 1
- HLXFHYCWWFUOSC-IULAOUEKSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(2-chlorophenyl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3C=CC=CC=3)C=3C(=CC=CC=3)Cl)[N+]21CC(=O)NC=1C=CON=1 HLXFHYCWWFUOSC-IULAOUEKSA-N 0.000 claims 1
- DOFPJTZAWLYUGW-FIQQBEOASA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 DOFPJTZAWLYUGW-FIQQBEOASA-N 0.000 claims 1
- QURMEKJIUAZANR-FVRMQZBVSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclobutyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCC1 QURMEKJIUAZANR-FVRMQZBVSA-N 0.000 claims 1
- JKNHJSSAZYNMIW-FIQQBEOASA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 JKNHJSSAZYNMIW-FIQQBEOASA-N 0.000 claims 1
- JBYALQATTNNXLM-ROILBPFPSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 JBYALQATTNNXLM-ROILBPFPSA-N 0.000 claims 1
- UYDZCDBOKNTCDY-NSLDKZMESA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 UYDZCDBOKNTCDY-NSLDKZMESA-N 0.000 claims 1
- MUNWNMDXVFWWSJ-FIQQBEOASA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 MUNWNMDXVFWWSJ-FIQQBEOASA-N 0.000 claims 1
- BQJVDKLIOBNQRU-JMYPFRHISA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C1=COC=C1)(O)C1CCCC1 BQJVDKLIOBNQRU-JMYPFRHISA-N 0.000 claims 1
- IPYXMSOXADDKER-SUSCGCCGSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 IPYXMSOXADDKER-SUSCGCCGSA-N 0.000 claims 1
- PFNWPHKQGJNTSN-UTEXUTGQSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 PFNWPHKQGJNTSN-UTEXUTGQSA-N 0.000 claims 1
- GUOWKYWHJRLGRT-VTTAHNPLSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopropyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC2=NOC=C2)C1)C(=O)C(C=1SC=CC=1)(O)C1CC1 GUOWKYWHJRLGRT-VTTAHNPLSA-N 0.000 claims 1
- GUHYQPHICDOZIV-DMWRAEOSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-ethylsulfanyl-2,2-diphenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(SCC)(C=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 GUHYQPHICDOZIV-DMWRAEOSSA-N 0.000 claims 1
- XFDIKUJEOXYVQO-PKLCTQDOSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-bis(3-methoxyphenyl)acetate;bromide Chemical compound [Br-].COC1=CC=CC(C(O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=C(OC)C=CC=2)=C1 XFDIKUJEOXYVQO-PKLCTQDOSA-N 0.000 claims 1
- JASBHIMHORBWBD-PKLCTQDOSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-bis(4-methoxyphenyl)acetate;bromide Chemical compound [Br-].C1=CC(OC)=CC=C1C(O)(C=1C=CC(OC)=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 JASBHIMHORBWBD-PKLCTQDOSA-N 0.000 claims 1
- LMVPTKHKZQNMTP-DMWRAEOSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-bis(4-methylphenyl)acetate;bromide Chemical compound [Br-].C1=CC(C)=CC=C1C(O)(C=1C=CC(C)=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 LMVPTKHKZQNMTP-DMWRAEOSSA-N 0.000 claims 1
- KQZGFLAOVMRBJE-FKYYSRDKSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC=1C=CON=1 KQZGFLAOVMRBJE-FKYYSRDKSA-N 0.000 claims 1
- KNRAZWQROOQZCD-HIPLPVRDSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-(2-methoxyphenyl)-2-phenylacetate;bromide Chemical compound [Br-].COC1=CC=CC=C1C(O)(C=1C=CC=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 KNRAZWQROOQZCD-HIPLPVRDSA-N 0.000 claims 1
- SQKMLNPPWDJIOV-KNNDMWINSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-(2-methylphenyl)-2-phenylacetate;bromide Chemical compound [Br-].CC1=CC=CC=C1C(O)(C=1C=CC=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 SQKMLNPPWDJIOV-KNNDMWINSA-N 0.000 claims 1
- UKIGHUJEPXNYAZ-HIPLPVRDSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-(4-methoxyphenyl)-2-phenylacetate;bromide Chemical compound [Br-].C1=CC(OC)=CC=C1C(O)(C=1C=CC=CC=1)C(=O)O[C@@H]1C(CC2)CC[N+]2(CC(=O)NC2=NOC=C2)C1 UKIGHUJEPXNYAZ-HIPLPVRDSA-N 0.000 claims 1
- VTBLMPHPICFVKP-FIQQBEOASA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 VTBLMPHPICFVKP-FIQQBEOASA-N 0.000 claims 1
- QJIBWXVASULUCW-WULMZJJMSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-methoxy-2,2-diphenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(OC)(C=3C=CC=CC=3)C=3C=CC=CC=3)[N+]21CC(=O)NC=1C=CON=1 QJIBWXVASULUCW-WULMZJJMSA-N 0.000 claims 1
- DAKBDLXZFNNQTD-RTDUGLMJSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC=1C=CON=1 DAKBDLXZFNNQTD-RTDUGLMJSA-N 0.000 claims 1
- IDKPHFMVEHJQHS-RTDUGLMJSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC=1C=CON=1 IDKPHFMVEHJQHS-RTDUGLMJSA-N 0.000 claims 1
- BZWAIILYUZPDDF-YUXMWEGSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4C4=CC=CC=C43)CC[N+]12CC(=O)NC=1C=CON=1 BZWAIILYUZPDDF-YUXMWEGSSA-N 0.000 claims 1
- ZLXHOBGHKNOVHH-YUXMWEGSSA-N [(3r)-1-[2-(1,2-oxazol-3-ylamino)-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC=1C=CON=1 ZLXHOBGHKNOVHH-YUXMWEGSSA-N 0.000 claims 1
- YPNWAUAZEBXEDV-DXLVBJHUSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=COC=C2)C2=COC=C2)=N1 YPNWAUAZEBXEDV-DXLVBJHUSA-N 0.000 claims 1
- YSLCOKGCOCSEPO-WQKGMRGTSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(2-chlorophenyl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C(=CC=CC=2)Cl)=N1 YSLCOKGCOCSEPO-WQKGMRGTSA-N 0.000 claims 1
- ILKKYAURZDXSSS-OANMHNKXSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=COC=C2)C=2C=CC=CC=2)=N1 ILKKYAURZDXSSS-OANMHNKXSA-N 0.000 claims 1
- UTLGONQMBRVFOI-PBYMMPLCSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclobutyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCC2)C=2SC=CC=2)=N1 UTLGONQMBRVFOI-PBYMMPLCSA-N 0.000 claims 1
- LTWYADDGFGLFLX-OANMHNKXSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCCC2)C2=CSC=C2)=N1 LTWYADDGFGLFLX-OANMHNKXSA-N 0.000 claims 1
- ACHOBFNJGCSMLX-HLESCNFNSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCC2)C2=COC=C2)=N1 ACHOBFNJGCSMLX-HLESCNFNSA-N 0.000 claims 1
- PSIHJGFSCZDQJM-HLESCNFNSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCC2)C2=CSC=C2)=N1 PSIHJGFSCZDQJM-HLESCNFNSA-N 0.000 claims 1
- QVPAEXCVBGXRLP-DXLVBJHUSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=CSC=C2)C2=CSC=C2)=N1 QVPAEXCVBGXRLP-DXLVBJHUSA-N 0.000 claims 1
- RCVVTPNGORUHNV-OANMHNKXSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=CSC=C2)C=2C=CC=CC=2)=N1 RCVVTPNGORUHNV-OANMHNKXSA-N 0.000 claims 1
- JNSNUESJPBPJFB-XCEOWTAJSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3CC3=CC=CC=C32)=N1 JNSNUESJPBPJFB-XCEOWTAJSA-N 0.000 claims 1
- JYGVFVNWVFASAH-XCEOWTAJSA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3CC3=CC=CC=C32)=N1 JYGVFVNWVFASAH-XCEOWTAJSA-N 0.000 claims 1
- BFZONOOZVKTCME-CJYZSSDISA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3OC3=CC=CC=C32)=N1 BFZONOOZVKTCME-CJYZSSDISA-N 0.000 claims 1
- XAPIRXONNQLWIT-CJYZSSDISA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3C3=CC=CC=C32)=N1 XAPIRXONNQLWIT-CJYZSSDISA-N 0.000 claims 1
- DEDIGANFAOGJEA-CJYZSSDISA-N [(3r)-1-[2-[(5-ethyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].O1C(CC)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3OC3=CC=CC=C32)=N1 DEDIGANFAOGJEA-CJYZSSDISA-N 0.000 claims 1
- HXEXVYRMUSSNCH-ZJKFLMFHSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3C=CC3=CC=CC=C32)=N1 HXEXVYRMUSSNCH-ZJKFLMFHSA-N 0.000 claims 1
- UJEGNJDPSAYEKZ-FKBRAVIBSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=COC=C2)C2=COC=C2)=N1 UJEGNJDPSAYEKZ-FKBRAVIBSA-N 0.000 claims 1
- WTQSSEGZNBJVOB-VYIGTOTHSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(2-chlorophenyl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C(=CC=CC=2)Cl)=N1 WTQSSEGZNBJVOB-VYIGTOTHSA-N 0.000 claims 1
- JOMHYNAWONELCA-SUSCGCCGSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=COC=C2)C=2C=CC=CC=2)=N1 JOMHYNAWONELCA-SUSCGCCGSA-N 0.000 claims 1
- RJKIEYOHIQSNMU-UTEXUTGQSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclobutyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCC2)C=2SC=CC=2)=N1 RJKIEYOHIQSNMU-UTEXUTGQSA-N 0.000 claims 1
- VFEGPHAWGSNMOD-SUSCGCCGSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCCC2)C2=COC=C2)=N1 VFEGPHAWGSNMOD-SUSCGCCGSA-N 0.000 claims 1
- YNFBYINXTBJLAC-SUSCGCCGSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCCC2)C2=CSC=C2)=N1 YNFBYINXTBJLAC-SUSCGCCGSA-N 0.000 claims 1
- WIQJVHQRIJIIIT-NSLDKZMESA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCC2)C=2OC=CC=2)=N1 WIQJVHQRIJIIIT-NSLDKZMESA-N 0.000 claims 1
- DRJQIJVVNXCFIL-FIQQBEOASA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CCCC2)C2=COC=C2)=N1 DRJQIJVVNXCFIL-FIQQBEOASA-N 0.000 claims 1
- RLIHYEQLMBPUPE-FVRMQZBVSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopropyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2CC2)C=2SC=CC=2)=N1 RLIHYEQLMBPUPE-FVRMQZBVSA-N 0.000 claims 1
- YBQUOFVNBMCGCF-FKBRAVIBSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=CSC=C2)C2=CSC=C2)=N1 YBQUOFVNBMCGCF-FKBRAVIBSA-N 0.000 claims 1
- GHWDLGZAQGDKCA-SUSCGCCGSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C2=CSC=C2)C=2C=CC=CC=2)=N1 GHWDLGZAQGDKCA-SUSCGCCGSA-N 0.000 claims 1
- BAJKRLDRJMTAPQ-PKLCTQDOSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3CC3=CC=CC=C32)=N1 BAJKRLDRJMTAPQ-PKLCTQDOSA-N 0.000 claims 1
- HSRJLUDXMMAKFW-PKLCTQDOSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3CC3=CC=CC=C32)=N1 HSRJLUDXMMAKFW-PKLCTQDOSA-N 0.000 claims 1
- ORONXPJTLSUYAG-RTDUGLMJSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(O)C3=CC=CC=C3OC3=CC=CC=C32)=N1 ORONXPJTLSUYAG-RTDUGLMJSA-N 0.000 claims 1
- USIMCYSRHQZCOQ-RTDUGLMJSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3C3=CC=CC=C32)=N1 USIMCYSRHQZCOQ-RTDUGLMJSA-N 0.000 claims 1
- DKCODRXMQIFZBL-RTDUGLMJSA-N [(3r)-1-[2-[(5-methyl-1,2-oxazol-3-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].O1C(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2C3=CC=CC=C3OC3=CC=CC=C32)=N1 DKCODRXMQIFZBL-RTDUGLMJSA-N 0.000 claims 1
- RKGNQYRWOANOMP-FKEZYDJSSA-N [(3r)-1-[2-amino-2-oxo-1-(1,3,5-triazin-2-yl)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)CC[N+]12C(C(=O)N)C1=NC=NC=N1 RKGNQYRWOANOMP-FKEZYDJSSA-N 0.000 claims 1
- FWBDUQHLLIWQPZ-NSOJYXMXSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=NC=NC=N1 FWBDUQHLLIWQPZ-NSOJYXMXSA-N 0.000 claims 1
- GGSBTIUOMADSDN-YSAQQSICSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=NC=NC=N1 GGSBTIUOMADSDN-YSAQQSICSA-N 0.000 claims 1
- XBHHWDUIBLQRJI-NOWPHXOYSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 XBHHWDUIBLQRJI-NOWPHXOYSA-N 0.000 claims 1
- NWBVZKXXTJBIMK-YSAQQSICSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 NWBVZKXXTJBIMK-YSAQQSICSA-N 0.000 claims 1
- ILVLVFWRALKHCJ-DFUUOGHFSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 ILVLVFWRALKHCJ-DFUUOGHFSA-N 0.000 claims 1
- OBLKUAOGTWYWDH-NOWPHXOYSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 OBLKUAOGTWYWDH-NOWPHXOYSA-N 0.000 claims 1
- PYCJKYAGHQMPCB-YSAQQSICSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 PYCJKYAGHQMPCB-YSAQQSICSA-N 0.000 claims 1
- XEFQMFZTUHWAAO-KMIFLNSOSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 XEFQMFZTUHWAAO-KMIFLNSOSA-N 0.000 claims 1
- CHEJEFSNPMQJRZ-YHRORWFSSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 CHEJEFSNPMQJRZ-YHRORWFSSA-N 0.000 claims 1
- NUSSSVNHXDWJET-KMIFLNSOSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 NUSSSVNHXDWJET-KMIFLNSOSA-N 0.000 claims 1
- RSRZRXSREIBLKA-UXHKZPOWSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CN=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCC1 RSRZRXSREIBLKA-UXHKZPOWSA-N 0.000 claims 1
- NYNBJOURLGSFHV-NSOJYXMXSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=NC=NC=N1 NYNBJOURLGSFHV-NSOJYXMXSA-N 0.000 claims 1
- NEWXOMFLRSEFQU-YSAQQSICSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=NC=NC=N1 NEWXOMFLRSEFQU-YSAQQSICSA-N 0.000 claims 1
- DEODHGSTQZRJAR-OASTYHRRSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC1=NC=NC=N1 DEODHGSTQZRJAR-OASTYHRRSA-N 0.000 claims 1
- HBDHQNASIFJDMR-OASTYHRRSA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=NC=NC=N1 HBDHQNASIFJDMR-OASTYHRRSA-N 0.000 claims 1
- SSEUVGQKRYVPBR-OFIQDHIESA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CC(=O)NC1=NC=NC=N1 SSEUVGQKRYVPBR-OFIQDHIESA-N 0.000 claims 1
- QNJOKWDGICCMGR-OFIQDHIESA-N [(3r)-1-[2-oxo-2-(1,3,5-triazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=NC=NC=N1 QNJOKWDGICCMGR-OFIQDHIESA-N 0.000 claims 1
- XTQWLMJWVILPLV-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=CN=CC=N1 XTQWLMJWVILPLV-WHPWLWEVSA-N 0.000 claims 1
- WFHLUCIMTYUEBR-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CN=CC=N1 WFHLUCIMTYUEBR-QVOXVMGDSA-N 0.000 claims 1
- GZNVXBRNMFONBM-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 GZNVXBRNMFONBM-YGXSZZIWSA-N 0.000 claims 1
- VTFGHQOKBDCJRA-WNCQOFSISA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 VTFGHQOKBDCJRA-WNCQOFSISA-N 0.000 claims 1
- GDIDDJZPLUFRLC-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 GDIDDJZPLUFRLC-YGXSZZIWSA-N 0.000 claims 1
- YYFZLFYVXCVDIT-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 YYFZLFYVXCVDIT-QVOXVMGDSA-N 0.000 claims 1
- HLKWSDNOBXLJTF-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=NC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCC1 HLKWSDNOBXLJTF-BDVUIUMHSA-N 0.000 claims 1
- QLMOJOJZOMDMNW-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=CN=CC=N1 QLMOJOJZOMDMNW-WHPWLWEVSA-N 0.000 claims 1
- MEWVUKMLGXIVMX-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CN=CC=N1 MEWVUKMLGXIVMX-QVOXVMGDSA-N 0.000 claims 1
- ZCIMJCILQZIZTC-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CC=N1 ZCIMJCILQZIZTC-LNORMHFUSA-N 0.000 claims 1
- LJNYWXYTSQSFRH-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CC=N1 LJNYWXYTSQSFRH-LNORMHFUSA-N 0.000 claims 1
- KELKXMKWBZVARH-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CC=N1 KELKXMKWBZVARH-SGFHCSRJSA-N 0.000 claims 1
- WUJYVHUCCLKWKW-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4C4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CC=N1 WUJYVHUCCLKWKW-SGFHCSRJSA-N 0.000 claims 1
- BXAQTQSNHWPVFY-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CC=N1 BXAQTQSNHWPVFY-SGFHCSRJSA-N 0.000 claims 1
- PDGAHRBJCQCRPZ-XLKOHVDKSA-N [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)[N+]21CC(=O)NC1=CC=CC=N1 PDGAHRBJCQCRPZ-XLKOHVDKSA-N 0.000 claims 1
- DZIZKRWZUCSZLP-ROILBPFPSA-N [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CC=CC=N1 DZIZKRWZUCSZLP-ROILBPFPSA-N 0.000 claims 1
- DLBQMPBEOZQBAY-NVJOYBRVSA-N [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=CC=CC=N1 DLBQMPBEOZQBAY-NVJOYBRVSA-N 0.000 claims 1
- IMZUFXGEXYQVPC-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=NC=CC=N1 IMZUFXGEXYQVPC-WHPWLWEVSA-N 0.000 claims 1
- CDBOJSYPKSLCAQ-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 CDBOJSYPKSLCAQ-YGXSZZIWSA-N 0.000 claims 1
- HWBRWDLMEZLCFM-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 HWBRWDLMEZLCFM-QVOXVMGDSA-N 0.000 claims 1
- PEFOWOYEHBJITF-WNCQOFSISA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 PEFOWOYEHBJITF-WNCQOFSISA-N 0.000 claims 1
- PTXMAWMLZHIOEP-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 PTXMAWMLZHIOEP-YGXSZZIWSA-N 0.000 claims 1
- HMGQOEGPGTXZLJ-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 HMGQOEGPGTXZLJ-AYFIPJBYSA-N 0.000 claims 1
- PUTZVIMHMIDAJN-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCC1 PUTZVIMHMIDAJN-BDVUIUMHSA-N 0.000 claims 1
- UHNAGLQQLRRVGH-ZVPZRTFFSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 UHNAGLQQLRRVGH-ZVPZRTFFSA-N 0.000 claims 1
- LQSPCDHPVNKHMN-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 LQSPCDHPVNKHMN-AYFIPJBYSA-N 0.000 claims 1
- HUIUSUAROAOBLQ-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CC=CN=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCC1 HUIUSUAROAOBLQ-BDVUIUMHSA-N 0.000 claims 1
- VNHVFUQTCCGRTQ-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=NC=CC=N1 VNHVFUQTCCGRTQ-WHPWLWEVSA-N 0.000 claims 1
- DIWDICYHMOAPRL-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=NC=CC=N1 DIWDICYHMOAPRL-QVOXVMGDSA-N 0.000 claims 1
- YZPBSTOKTIAJRI-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC1=NC=CC=N1 YZPBSTOKTIAJRI-LNORMHFUSA-N 0.000 claims 1
- HLASKHSYFAXUIS-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=NC=CC=N1 HLASKHSYFAXUIS-SGFHCSRJSA-N 0.000 claims 1
- HUEDRJVKOUXUAU-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=NC=CC=N1 HUEDRJVKOUXUAU-SGFHCSRJSA-N 0.000 claims 1
- XRUYSILIWCNGBE-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=CC=NC=N1 XRUYSILIWCNGBE-WHPWLWEVSA-N 0.000 claims 1
- OEYHQTXLMJHSOB-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CC=NC=N1 OEYHQTXLMJHSOB-QVOXVMGDSA-N 0.000 claims 1
- NJFVAMNYKFYERH-YGXSZZIWSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 NJFVAMNYKFYERH-YGXSZZIWSA-N 0.000 claims 1
- VBIYLYUWXZELLQ-WNCQOFSISA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 VBIYLYUWXZELLQ-WNCQOFSISA-N 0.000 claims 1
- HYHOFJXUEWBJOB-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 HYHOFJXUEWBJOB-QVOXVMGDSA-N 0.000 claims 1
- PUOMOFCXVAAXCE-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 PUOMOFCXVAAXCE-AYFIPJBYSA-N 0.000 claims 1
- FUGGBRBLEUYEIP-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCC1 FUGGBRBLEUYEIP-BDVUIUMHSA-N 0.000 claims 1
- QGJDAWHXJGNHNS-ZVPZRTFFSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 QGJDAWHXJGNHNS-ZVPZRTFFSA-N 0.000 claims 1
- NINFWSUPOJXCOM-AYFIPJBYSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 NINFWSUPOJXCOM-AYFIPJBYSA-N 0.000 claims 1
- WRRCJHMXWXUJAD-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2N=CN=CC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCC1 WRRCJHMXWXUJAD-BDVUIUMHSA-N 0.000 claims 1
- DFGHFDKLUVABAW-WHPWLWEVSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=CC=NC=N1 DFGHFDKLUVABAW-WHPWLWEVSA-N 0.000 claims 1
- DDJBAJDWPDCKNP-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CC=NC=N1 DDJBAJDWPDCKNP-QVOXVMGDSA-N 0.000 claims 1
- KELOTVXGBURWDT-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4CC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CC=NC=N1 KELOTVXGBURWDT-LNORMHFUSA-N 0.000 claims 1
- BASRJFATTNGULG-LNORMHFUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=CC=NC=N1 BASRJFATTNGULG-LNORMHFUSA-N 0.000 claims 1
- GBFGPOWJLPODQG-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=CC=NC=N1 GBFGPOWJLPODQG-SGFHCSRJSA-N 0.000 claims 1
- VPSQEXUYUGDHSR-SGFHCSRJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-4-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CC=NC=N1 VPSQEXUYUGDHSR-SGFHCSRJSA-N 0.000 claims 1
- DGNMUQUXQWLGQN-WWAPZXQFSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 11-hydroxydibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C=CC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CN=C1 DGNMUQUXQWLGQN-WWAPZXQFSA-N 0.000 claims 1
- QSQDXNCTHMRZPS-DXLVBJHUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C3=COC=C3)[N+]21CC(=O)NC1=CN=CN=C1 QSQDXNCTHMRZPS-DXLVBJHUSA-N 0.000 claims 1
- CXNXVWKVLHDHJZ-AVRGKSJGSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-3-yl)-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=COC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CN=CN=C1 CXNXVWKVLHDHJZ-AVRGKSJGSA-N 0.000 claims 1
- IBFHCPMNGCRVGP-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCCC1 IBFHCPMNGCRVGP-QVOXVMGDSA-N 0.000 claims 1
- XRHXDEOWHHDRGS-AVRGKSJGSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCCC1 XRHXDEOWHHDRGS-AVRGKSJGSA-N 0.000 claims 1
- SJLLTBPMESHADM-CXEAGMIJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 SJLLTBPMESHADM-CXEAGMIJSA-N 0.000 claims 1
- YIHPGYTUXLBQJB-QVOXVMGDSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCCC1 YIHPGYTUXLBQJB-QVOXVMGDSA-N 0.000 claims 1
- BRILMVBXECABEL-AVRGKSJGSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C1=CSC=C1)(O)C1CCCCC1 BRILMVBXECABEL-AVRGKSJGSA-N 0.000 claims 1
- CBCSMHWZCBFINO-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-2-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1OC=CC=1)(O)C1CCCC1 CBCSMHWZCBFINO-BDVUIUMHSA-N 0.000 claims 1
- UYFKNXVQKKUIIT-FGXDWOATSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-(furan-3-yl)-2-hydroxyacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C1=COC=C1)(O)C1CCCC1 UYFKNXVQKKUIIT-FGXDWOATSA-N 0.000 claims 1
- RVZBZXKTDZTEDW-AFHFFQAUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCC1 RVZBZXKTDZTEDW-AFHFFQAUSA-N 0.000 claims 1
- DUYCENKMMAZWNR-BDVUIUMHSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclopentyl-2-hydroxy-2-thiophen-2-ylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C=NC=NC=2)C1)C(=O)C(C=1SC=CC=1)(O)C1CCCC1 DUYCENKMMAZWNR-BDVUIUMHSA-N 0.000 claims 1
- DMFLXIOETUDIRP-DXLVBJHUSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-di(thiophen-3-yl)acetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C3=CSC=C3)[N+]21CC(=O)NC1=CN=CN=C1 DMFLXIOETUDIRP-DXLVBJHUSA-N 0.000 claims 1
- DQHCQNAXJMUYBD-AVRGKSJGSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-3-ylacetate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C(O)(C3=CSC=C3)C=3C=CC=CC=3)[N+]21CC(=O)NC1=CN=CN=C1 DQHCQNAXJMUYBD-AVRGKSJGSA-N 0.000 claims 1
- BYBFJHNMVLBVBU-XCEOWTAJSA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxy-10h-anthracene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4CC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CN=C1 BYBFJHNMVLBVBU-XCEOWTAJSA-N 0.000 claims 1
- XPXSBGICJHODQB-CJYZSSDISA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyfluorene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CN=C1 XPXSBGICJHODQB-CJYZSSDISA-N 0.000 claims 1
- LOGKHQPVIHNRQC-CJYZSSDISA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate;bromide Chemical compound [Br-].C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CC(=O)NC1=CN=CN=C1 LOGKHQPVIHNRQC-CJYZSSDISA-N 0.000 claims 1
- SZUGBQXPVVBDJC-CJYZSSDISA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-fluorene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4C4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CN=C1 SZUGBQXPVVBDJC-CJYZSSDISA-N 0.000 claims 1
- HBHKKIXTJCXTEU-CJYZSSDISA-N [(3r)-1-[2-oxo-2-(pyrimidin-5-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9h-xanthene-9-carboxylate;bromide Chemical compound [Br-].C1CC([C@H](C2)OC(=O)C3C4=CC=CC=C4OC4=CC=CC=C43)CC[N+]12CC(=O)NC1=CN=CN=C1 HBHKKIXTJCXTEU-CJYZSSDISA-N 0.000 claims 1
- KVRBYPPMUIHVSM-NXCMLHJESA-N [(3r)-1-[2-oxo-2-[(4-phenyl-1,2-oxazol-3-yl)amino]ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].O([C@@H]1C2CC[N+](CC2)(CC(=O)NC=2C(=CON=2)C=2C=CC=CC=2)C1)C(=O)C(C=1C=CC=CC=1)(O)C1CCCCC1 KVRBYPPMUIHVSM-NXCMLHJESA-N 0.000 claims 1
- KWOSOGIXVROBEO-RSYBFYOOSA-N [O-]P([O-])([O-])=O.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1 Chemical compound [O-]P([O-])([O-])=O.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2C=CC=CC=2)CCCCC1 KWOSOGIXVROBEO-RSYBFYOOSA-N 0.000 claims 1
- PWFMLWUCJBKRTI-IVPFZVFJSA-N [O-]P([O-])([O-])=O.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1 Chemical compound [O-]P([O-])([O-])=O.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1.C1([C@](O)(C(=O)O[C@@H]2C3CC[N+](CC3)(CC(=O)NC3=NOC=C3)C2)C=2SC=CC=2)CCCCC1 PWFMLWUCJBKRTI-IVPFZVFJSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 239000011630 iodine Chemical group 0.000 claims 1
- 229910052740 iodine Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0424284.8A GB0424284D0 (en) | 2004-11-02 | 2004-11-02 | Organic compounds |
PCT/EP2005/011662 WO2006048225A1 (en) | 2004-11-02 | 2005-10-31 | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20100693T1 true HRP20100693T1 (hr) | 2011-01-31 |
Family
ID=33515948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20100693T HRP20100693T1 (hr) | 2004-11-02 | 2010-12-14 | Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora |
Country Status (33)
Country | Link |
---|---|
US (2) | US7723356B2 (bg) |
EP (2) | EP1811999B1 (bg) |
JP (1) | JP4950896B2 (bg) |
KR (1) | KR101252307B1 (bg) |
CN (1) | CN101056634B (bg) |
AR (1) | AR054090A1 (bg) |
AT (1) | ATE481099T1 (bg) |
AU (1) | AU2005300710B2 (bg) |
BR (1) | BRPI0517945A (bg) |
CA (1) | CA2583237C (bg) |
CY (1) | CY1110952T1 (bg) |
DE (1) | DE602005023639D1 (bg) |
DK (1) | DK1811999T3 (bg) |
EC (1) | ECSP077424A (bg) |
ES (1) | ES2353142T3 (bg) |
GB (1) | GB0424284D0 (bg) |
HR (1) | HRP20100693T1 (bg) |
IL (1) | IL182695A0 (bg) |
JO (1) | JO2613B1 (bg) |
MA (1) | MA29080B1 (bg) |
MX (1) | MX2007005189A (bg) |
MY (1) | MY145207A (bg) |
NO (1) | NO20072371L (bg) |
NZ (1) | NZ554302A (bg) |
PE (1) | PE20060609A1 (bg) |
PL (1) | PL1811999T3 (bg) |
PT (1) | PT1811999E (bg) |
RU (1) | RU2399620C2 (bg) |
SI (1) | SI1811999T1 (bg) |
TN (1) | TNSN07164A1 (bg) |
TW (1) | TW200628154A (bg) |
WO (1) | WO2006048225A1 (bg) |
ZA (1) | ZA200702772B (bg) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
BRPI0614290A2 (pt) | 2005-08-08 | 2011-03-22 | Argenta Discovery Ltd | derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos |
EP1940775A2 (en) | 2005-08-11 | 2008-07-09 | University of Massachusetts | Methods and compositions for the efficient delivery of therapeutic agents to cells and animals |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
UY30714A1 (es) * | 2006-11-14 | 2008-07-03 | Astrazeneca Ab | Compuestos sustituidos con 3-{ [(1-arilcicloheptil)carbonil]oxi} -1-azoniabiciclo, derivados monovalentes o polivalentes de los mismos, composiciones farmacéuticas, métodos de preparacion y aplicaciones. |
US20100113510A1 (en) * | 2006-12-19 | 2010-05-06 | Rhonan Ford | Quinuclidinol derivatives as muscarinic receptor antagonists |
PL2197841T3 (pl) | 2007-09-07 | 2012-04-30 | Theravance Inc | Związki zawierające guanidynę przydatne jako antagoniści receptorów |
WO2009079392A1 (en) | 2007-12-14 | 2009-06-25 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
PL2231642T3 (pl) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pirymidyny jako inhibitory kinazy |
EP2300464A1 (en) | 2008-05-13 | 2011-03-30 | AstraZeneca AB | Quinuclidine derivatives as muscarinic m3 receptor antagonists |
GB0808707D0 (en) * | 2008-05-13 | 2008-06-18 | Argenta Discovery Ltd | New compounds 275 |
WO2009139708A1 (en) * | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST |
GB0808708D0 (en) * | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
US20090326004A1 (en) * | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
WO2009153536A1 (en) * | 2008-06-17 | 2009-12-23 | Argenta Discovery Limited | 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists |
GB0811100D0 (en) * | 2008-06-17 | 2008-07-23 | Astrazeneca Ab | New combination |
US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
US20120022127A1 (en) | 2009-04-09 | 2012-01-26 | Thomas Allmendinger | Process for preparing pyrrolidinium salts |
BR112012032333A2 (pt) * | 2010-06-22 | 2016-11-08 | Chiesi Farma Spa | composto, uso de um composto, composição farmacêutica, combinação de um composto e dispositivo |
SG186427A1 (en) * | 2010-06-22 | 2013-01-30 | Chiesi Farma Spa | Dry powder formulation comprising an antimuscarinic drug |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
CA2828219A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
JP2011195593A (ja) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | ムスカリンm3受容体アンタゴニストとしてのキヌクリジン誘導体 |
EA028509B1 (ru) | 2012-12-19 | 2017-11-30 | Новартис Аг | Ингибиторы аутотаксина, фармацевтические композиции и комбинации, содержащие их, и их применение в лечении заболеваний и состояний, опосредованных аутотаксином |
WO2015162558A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Autotaxin inhibitors |
CA3193201A1 (en) * | 2014-05-06 | 2015-11-12 | Anthony G. Visco | Methods of treating or preventing preterm labor |
CN109851615B (zh) * | 2019-04-22 | 2021-06-08 | 上海旭东海普药业有限公司 | 纯化戊乙奎醚的方法 |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3833592A (en) | 1966-05-31 | 1974-09-03 | Little Inc A | Tropanyl alpha,alpha-diphenyl-alpha-fluoroacetate esters |
GB1219606A (en) * | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
GB8916480D0 (en) | 1989-07-19 | 1989-09-06 | Glaxo Group Ltd | Chemical process |
PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
JP3251587B2 (ja) | 1992-04-02 | 2002-01-28 | スミスクライン・ビーチャム・コーポレイション | 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物 |
CA2133439C (en) | 1992-04-02 | 2005-07-26 | Siegfried Benjamin Christensen, Iv | Compounds useful for treating allergic and inflammatory diseases |
WO1993019750A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating allergic or inflammatory diseases |
GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
GB9414193D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
GB9414208D0 (en) | 1994-07-14 | 1994-08-31 | Glaxo Group Ltd | Compounds |
GB9617730D0 (en) | 1996-08-23 | 1996-10-02 | Pfizer Ltd | Quarternary ammonium compounds |
GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
GB9723589D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
GB9723590D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
GB9723566D0 (en) | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
PE20000270A1 (es) | 1998-02-14 | 2000-05-20 | Glaxo Group Ltd | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
US6541669B1 (en) | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
IL140396A0 (en) | 1998-06-23 | 2002-02-10 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
GB9813565D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813535D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
GB9813540D0 (en) | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
CN1146616C (zh) | 1998-06-30 | 2004-04-21 | 陶氏环球技术公司 | 聚合物多元醇及其生产方法 |
CA2347512C (en) | 1998-10-16 | 2005-12-06 | Pfizer Inc. | Adenine derivatives |
GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
US6683115B2 (en) | 1999-06-02 | 2004-01-27 | Theravance, Inc. | β2-adrenergic receptor agonists |
GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
SI1212089T1 (sl) | 1999-08-21 | 2006-08-31 | Altana Pharma Ag | Sinergisticna kombinacija roflumilasta in salmeterola |
CO5180581A1 (es) | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
GB0003960D0 (en) | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
KR20020093083A (ko) | 2000-04-27 | 2002-12-12 | 베링거 잉겔하임 파르마 카게 | 신규한 완효성 베타모사체, 이의 제조방법 및 약제로서의이의 용도 |
TWI227240B (en) | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
GB0015727D0 (en) | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
JP5046465B2 (ja) * | 2000-06-27 | 2012-10-10 | ラボラトリオス・サルバト・ソシエダッド・アノニマ | アリールアルキルアミンから誘導されるカルバメート |
GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
BRPI0113042B8 (pt) | 2000-08-05 | 2021-05-25 | Glaxo Group Ltd | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato |
US6486172B2 (en) | 2000-08-18 | 2002-11-26 | Pharmacia & Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
AU2001284645A1 (en) | 2000-08-18 | 2002-03-04 | Pharmacia And Upjohn Company | Quinuclidine-substituted aryl compounds for treatment of disease |
JP2004506735A (ja) | 2000-08-18 | 2004-03-04 | ファルマシア・アンド・アップジョン・カンパニー | 疾患治療用キヌクリジン置換アリール化合物 |
US6500840B2 (en) | 2000-08-21 | 2002-12-31 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
US6599916B2 (en) | 2000-08-21 | 2003-07-29 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease |
WO2002016355A2 (en) | 2000-08-21 | 2002-02-28 | Pharmacia & Upjohn Company | Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands |
GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
RU2296762C2 (ru) | 2000-12-22 | 2007-04-10 | Альмиралль Продесфарма Аг | Карбаматы хинуклидина, способы их получения и фармацевтическая композиция на их основе |
US6476222B2 (en) | 2001-01-05 | 2002-11-05 | Sun Chemical Corporation | Preparation of heat stable pigment violet 23 |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
ES2288543T3 (es) | 2001-03-08 | 2008-01-16 | Glaxo Group Limited | Agonistas de beta-adrenorreceptores. |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
ATE381537T1 (de) | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
CZ20032958A3 (en) | 2001-04-30 | 2004-03-17 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
KR20030097901A (ko) | 2001-05-25 | 2003-12-31 | 화이자 인코포레이티드 | 폐쇄성 기도 질환의 치료를 위한 아데노신 a2a 수용체작용제 및 항콜린제의 조합물 |
JP2005500290A (ja) | 2001-06-12 | 2005-01-06 | グラクソ グループ リミテッド | 抗炎症性の、17β−カルボチオアートアンドロスタン誘導体である17α複素環エステル |
EP1425001B1 (en) | 2001-09-14 | 2008-12-17 | Glaxo Group Limited | Phenethanolamine derivatives for treatment of respiratory diseases |
GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
WO2003048181A1 (en) | 2001-12-01 | 2003-06-12 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
KR100944580B1 (ko) | 2001-12-20 | 2010-02-25 | 치에시 파마슈티시 에스.피.아. | 1-알킬-1-아조니아비시클로[2.2.2]옥탄 카르바메이트유도체 및 이의 무스카린 수용체 길항제로서의 용도 |
WO2003072592A1 (en) | 2002-01-15 | 2003-09-04 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
NZ535889A (en) | 2002-03-26 | 2006-03-31 | Boehringer Ingelheim Pharma | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
JP2006515829A (ja) | 2002-04-10 | 2006-06-08 | ユニバーシティ オブ バージニア パテント ファウンデーション | 炎症性疾病の処置のための、a2aアデノシン受容体アゴニストの使用 |
CA2481320A1 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
AU2003239880A1 (en) | 2002-05-28 | 2003-12-12 | Theravance, Inc. | ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS |
US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
ES2203327B1 (es) | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
JP2006502104A (ja) | 2002-06-25 | 2006-01-19 | メルク フロスト カナダ アンド カンパニー | 8−(ビアリール)キノリンpde4阻害剤 |
JP2005538972A (ja) | 2002-07-02 | 2005-12-22 | メルク フロスト カナダ アンド カンパニー | ジアリール置換エタンピリドンpde4阻害剤 |
AU2003281355A1 (en) | 2002-07-08 | 2004-01-23 | Pfizer Products Inc. | Modulators of the glucocorticoid receptor |
GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
PE20050130A1 (es) | 2002-08-09 | 2005-03-29 | Novartis Ag | Compuestos organicos |
WO2004018449A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
PL373146A1 (en) | 2002-08-10 | 2005-08-22 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
US7220746B2 (en) | 2002-08-10 | 2007-05-22 | Altana Pharma Ag | Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors |
AU2003260371A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
US20060116518A1 (en) | 2002-08-17 | 2006-06-01 | Altana Pharma Ag | Novel phenanthridines |
EP1581533A2 (en) | 2002-08-17 | 2005-10-05 | ALTANA Pharma AG | Novel benzonaphthyridines |
AU2003259747A1 (en) | 2002-08-21 | 2004-03-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
CA2495827C (en) | 2002-08-29 | 2012-05-08 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
DE60333371D1 (de) | 2002-08-29 | 2010-08-26 | Boehringer Ingelheim Pharma | 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen |
US7423046B2 (en) | 2002-08-29 | 2008-09-09 | Nycomed Gmbh | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
AU2003270783C1 (en) | 2002-09-20 | 2010-05-20 | Merck Sharp & Dohme Corp. | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
MXPA05003866A (es) | 2002-10-11 | 2005-06-22 | Pfizer | Derivados de indol como agonistas beta-2. |
EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
ATE369353T1 (de) | 2002-10-22 | 2007-08-15 | Glaxo Group Ltd | Medizinisch verwendbare arylethanolamin verbindungen |
EA010408B1 (ru) | 2002-10-23 | 2008-08-29 | Гленмарк Фармасьютикалс Лтд. | Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы |
CA2503588A1 (en) | 2002-10-28 | 2004-05-06 | Glaxo Group Limited | Phenethanolamine derivative for the treatment of respiratory diseases |
GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
US7732432B2 (en) | 2003-01-21 | 2010-06-08 | Merck Sharp & Dohme Corp. | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators |
EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
EP1615881A2 (en) | 2003-04-01 | 2006-01-18 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
DE602004019198D1 (de) | 2003-04-04 | 2009-03-12 | Novartis Ag | Chinolin-2-on-derivate zur behandlung von erkankungen der atemwege |
AR044134A1 (es) | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
EP1477167A1 (en) | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
US7268147B2 (en) | 2003-05-15 | 2007-09-11 | Pfizer Inc | Compounds useful for the treatment of diseases |
DE602004021921D1 (de) | 2003-05-28 | 2009-08-20 | Theravance Inc | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten |
CA2527334A1 (en) | 2003-06-04 | 2004-12-16 | Pfizer Inc. | 2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists |
GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
DE10332239B3 (de) | 2003-07-16 | 2005-03-03 | Framatome Anp Gmbh | Zirkoniumlegierung und Bauteile für den Kern von leichtwassergekühlten Kernreaktoren |
WO2005033121A2 (en) | 2003-10-03 | 2005-04-14 | King Pharmaceuticals Research & Development, Inc. | Synthesis of 2-aralkyloxyadenosines, 2-alkoxyadenosines, and their analogs |
GB0323701D0 (en) | 2003-10-09 | 2003-11-12 | Glaxo Group Ltd | Formulations |
GB0324654D0 (en) | 2003-10-22 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
GB0324886D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Medicinal compounds |
GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
US20050133417A1 (en) | 2003-12-19 | 2005-06-23 | Bhan Opinder K. | Systems, methods, and catalysts for producing a crude product |
DE102004001413A1 (de) | 2004-01-09 | 2005-08-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung |
TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
ES2239546B1 (es) * | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
MY144753A (en) | 2004-04-27 | 2011-10-31 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
ES2246170B1 (es) | 2004-07-29 | 2007-04-01 | Almirall Prodesfarma, S.A. | Nuevo procedimiento para preparar derivados de carbamato de quinuclidinio. |
-
2004
- 2004-11-02 GB GBGB0424284.8A patent/GB0424284D0/en not_active Ceased
-
2005
- 2005-10-12 JO JOP/2005/0145A patent/JO2613B1/ar active
- 2005-10-24 MY MYPI20054966A patent/MY145207A/en unknown
- 2005-10-31 PL PL05798470T patent/PL1811999T3/pl unknown
- 2005-10-31 CA CA2583237A patent/CA2583237C/en not_active Expired - Fee Related
- 2005-10-31 PE PE2005001274A patent/PE20060609A1/es not_active Application Discontinuation
- 2005-10-31 RU RU2007120454/04A patent/RU2399620C2/ru not_active IP Right Cessation
- 2005-10-31 JP JP2007538352A patent/JP4950896B2/ja not_active Expired - Fee Related
- 2005-10-31 WO PCT/EP2005/011662 patent/WO2006048225A1/en active Application Filing
- 2005-10-31 CN CN2005800380673A patent/CN101056634B/zh not_active Expired - Fee Related
- 2005-10-31 EP EP05798470A patent/EP1811999B1/en active Active
- 2005-10-31 AR ARP050104547A patent/AR054090A1/es not_active Application Discontinuation
- 2005-10-31 DK DK05798470.0T patent/DK1811999T3/da active
- 2005-10-31 MX MX2007005189A patent/MX2007005189A/es active IP Right Grant
- 2005-10-31 PT PT05798470T patent/PT1811999E/pt unknown
- 2005-10-31 US US11/577,417 patent/US7723356B2/en not_active Expired - Fee Related
- 2005-10-31 KR KR1020077009938A patent/KR101252307B1/ko not_active IP Right Cessation
- 2005-10-31 DE DE602005023639T patent/DE602005023639D1/de active Active
- 2005-10-31 NZ NZ554302A patent/NZ554302A/en not_active IP Right Cessation
- 2005-10-31 EP EP10156591A patent/EP2206499A1/en not_active Withdrawn
- 2005-10-31 SI SI200531188T patent/SI1811999T1/sl unknown
- 2005-10-31 BR BRPI0517945-9A patent/BRPI0517945A/pt not_active IP Right Cessation
- 2005-10-31 ES ES05798470T patent/ES2353142T3/es active Active
- 2005-10-31 AT AT05798470T patent/ATE481099T1/de active
- 2005-10-31 AU AU2005300710A patent/AU2005300710B2/en not_active Ceased
- 2005-11-01 TW TW094138292A patent/TW200628154A/zh unknown
-
2007
- 2007-04-03 ZA ZA200702772A patent/ZA200702772B/xx unknown
- 2007-04-19 IL IL182695A patent/IL182695A0/en unknown
- 2007-04-27 EC EC2007007424A patent/ECSP077424A/es unknown
- 2007-04-30 TN TNP2007000164A patent/TNSN07164A1/fr unknown
- 2007-05-08 NO NO20072371A patent/NO20072371L/no not_active Application Discontinuation
- 2007-05-30 MA MA29952A patent/MA29080B1/fr unknown
-
2010
- 2010-03-11 US US12/721,897 patent/US8084463B2/en not_active Expired - Fee Related
- 2010-11-25 CY CY20101101081T patent/CY1110952T1/el unknown
- 2010-12-14 HR HR20100693T patent/HRP20100693T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20100693T1 (hr) | Derivati kinuklidina i njihova uporaba kao antagonista muskarinskih m3 receptora | |
ES2710556T3 (es) | Compuesto inhibidor de Trk | |
ES2337241T3 (es) | Derivados de piperazina con actividad antagonista de receptores ccr1. | |
CN106573006A (zh) | 作为药物的rip1激酶抑制剂杂环酰胺 | |
TW200607807A (en) | Macrocyclic beta-secretase inhibitors | |
MA32692B1 (fr) | Procede de liberation d'une composition pharmaceutique a un patient qui en a besoin | |
WO2021150885A1 (en) | Cannabinoid derivatives | |
JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
EP3022201A1 (en) | Autotaxin inhibitors | |
CN103402995A (zh) | 新型吲哚、吲唑衍生物或其盐 | |
CN113164490A (zh) | 采用p2x3拮抗剂治疗瘙痒症 | |
GB2516138A (en) | The treatment of inflammatory disorders | |
Uto | 1, 2-Benzisoxazole compounds: a patent review (2009–2014) | |
JP2514163B2 (ja) | ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物 | |
AU2018347447B2 (en) | Methods and compositions for treating pruritus, xerosis, and associated disease using CCR3-inhibitors | |
JP2015534990A (ja) | 誤制御されたeIF4Eに関連する疾患又は障害を治療又は予防するための組成物及び方法 | |
SA05260389B1 (ar) | فينيل ببرازين تجمع بين الميل إلى مستقبلات دوبامين d2- ومواضع اعادة امتصاص السيروتونين | |
WO2021186180A1 (en) | Imidazolyl thiopehene sulfonyl carbamates for use in the treatment of diseases associated with angiotensin ii | |
CS277691A3 (en) | 3-/1h-indazol-3-yl/-4-pyridinamines, process and intermediates for their preparation and their application as medicaments | |
EP4211129A1 (en) | Thiophenoxime and furanoxime scaffolds | |
EP3134398A1 (en) | Autotaxin inhibitors | |
JPH02279673A (ja) | キノロン誘導体 | |
TH65078A (th) | อนุพันธ์ไพร์โรลิดีนออกซาไดอะโซล-และไทอะไดอะโซล |